CYCELRION THERAPEUTICS, INC.
245 First Street, 18th Floor
Cambridge, MA 02142
June 21, 2021
By EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Chris Edwards
| Re: | Cyclerion Therapeutics, Inc. (the “Company”) |
| Registration Statement on Form S-3 |
| File No. 333-257145
|
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests acceleration of the effective date of the above referenced Registration Statement to 4:00 p.m., Eastern time, on June 23, 2021, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Hughes Hubbard & Reed LLP, request by telephone that such Registration Statement be declared effective.
Please contact Gary J. Simon, of Hughes Hubbard & Reed LLP, special counsel to the Company, at (212) 837-6770, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
| Very truly yours, |
| | | |
| CYCLERION THERAPEUTICS, INC. |
| | | |
| By: | /s/ Anjeza Gjino |
| | Name: | Anjeza Gjino |
| | Title: | Chief Financial Office |
| cc: | Hughes Hubbard & Reed LLP |
